For its 2019 list, Fortune collected survey responses from more than 3,750 analysts, directors and executives who rated companies based on nine categories, including long-term investment value, innovation and social responsibility.
Pharmaceutical executives and non-pharmaceutical executives shared a positive view of J&J, helping the drugmaker claim the No. 17 spot on Fortune‘s “All-Star” list. It ranks among other big names such as Amazon, Apple, Starbucks and Netflix.
When assessing pharma companies, J&J finished first in each of the nine categories assessed. Seven other pharmaceutical companies made the list, including Merck, Roche, Novartis, Amgen, Bristol-Myers, Pfizer and AbbVie.
The placement on the Fortune list comes amid a string of negative news reports about J&J. In December, it was reported that the pharma company knew for decades that carcinogenic asbestos lurked in its baby powder.
This week, J&J paid $120 million to settle a lawsuit with 46 states, claiming that its DePuy unit used deceptive marketing techniques to sell its metal-on-metal hip implants.
More articles on pharmacy:
Bayer to shut down Pennsylvania plant, eliminate 600 jobs
New drug shortages rose 27% in 2018
FDA moves to fast-track OTC naloxone
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.